Stockscreener 앱 받기
5.995
0.50%
0.035
전일 마감가:
$5.96
열려 있는:
$6.06
하루 거래량:
513.24K
Relative Volume:
0.44
시가총액:
$466.83M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-1.972
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
+9.31%
1개월 성능:
+11.13%
6개월 성능:
+121.85%
1년 성능:
-0.99%
1일 변동 폭
$5.91
$6.18
1주일 범위
$5.215
$6.79
52주 변동 폭
$2.41
$7.37
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.995 | 464.10M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.24 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.48 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.91 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.44 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
How to monitor Solid Biosciences Inc. with trend dashboards2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Volume spikes in Solid Biosciences Inc. stock – what they meanJuly 2025 Rallies & AI Driven Stock Reports - newser.com
Is Solid Biosciences Inc. stock in correction or buying zoneMarket Activity Report & Safe Investment Capital Preservation Plans - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Is Solid Biosciences Inc. stock positioned for long term growthQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Using portfolio simulators with Solid Biosciences Inc. includedWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
Price momentum metrics for Solid Biosciences Inc. explainedQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com
Is Solid Biosciences Inc. stock ready for a breakoutTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street Zen - MarketBeat
Why Solid Biosciences Inc. stock is favored by pension fundsTrade Volume Report & Growth Oriented Trade Recommendations - newser.com
Visual trend scoring systems applied to Solid Biosciences Inc.Layoff News & Accurate Intraday Trading Signals - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Solid Biosciences (NASDAQ:SLDB) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Will Solid Biosciences Inc. stock attract ESG investors2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com
Solid Biosciences (NASDAQ:SLDB) Trading 22% HigherTime to Buy? - MarketBeat
Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital
Can Solid Biosciences Inc. stock deliver sustainable ROE2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Trend analysis for Solid Biosciences Inc. this weekForecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Solid Biosciences Inc. forming a bottoming baseMarket Trend Report & AI Optimized Trading Strategy Guides - newser.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewswire
Next-Gen Duchenne Muscular Dystrophy Treatment Update: Solid Bio's Gene Therapy Trial Results Coming - Stock Titan
Electrovaya Inc Stock Analysis and ForecastDividend Stability Analysis & Stay Invested. Stay Smart. - earlytimes.in
Solid Biosciences Inc. stock volume spike explainedMarket Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
What analysts say about Solid Biosciences Inc stockUtilities Sector Analysis & Free Daily Investment Newsletter Subscription - earlytimes.in
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
솔리드 바이오 주식 (SLDB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
1.19%
자본화:
|
볼륨(24시간):